… compared gefitinib plus chemotherapy with gefitinib in patients with untreated NSCLC
harboring EGFR mutations. This study compared the efficacy of chemotherapy alone and gefitinib …

… showed that erlotinib—a … studies have described activating mutations in advanced NSCLC
that made tumours more sensitive to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib…

… TKI (gefitinib or erlotinib) were excluded from this initial study. … independent study, treatment
with adjuvant erlotinib or gefitinib … In summary, we report the largest cohort of patients with …

… gefitinib efficacy were not reported in these studies. More recently, in two single-agent studies
with gefitinib, … 100 mg daily erlotinib or placebo plus gemcitabine cohort were included in …

… In this study, a total of 93 patients received afatinib at some point in their treatment; 70 … and
23 after either erlotinib or gefitinib. The median starting dose of afatinib in this study was 40 mg…

… Studies of second-generation EGFR inhibitors and other strategies are ongoing. Even after
the development of acquired resistance to gefitinib and/or erlotinib, … erlotinib and gefitinib …

… this study were compared to a historical cohort of all patients who received erlotinib after prior
failure to gefitinib … as for the patients who received afatinib in this study. All patients in this …

… The matched cohort consisted of 52 gefitinib and 52 AC patients … study (78.9%), although
a higher 2-year DFS rate (89%) was reported for patients treated with adjuvant erlotinib/gefitinib …

… The results of this study revealed the potential use of erlotinib for patients with stable disease
on prior gefitinib treatment and wild-type EGFR NSCLC, 13 the results are in line with the …

… study aimed to compare the relative survival rate of gefitinib, … The retrospective
population-based cohort study was … 20% in our cohort, and results exhibited that both erlotinib and …